8-K: NKGen Biotech to Acquire NKMax in Stalking Horse Bid, Securing Global IP Rights

NKGen Biotech has been selected as the stalking horse bidder to acquire NKMax, a South Korean biotech company, in a court-managed rehabilitation process, potentially securing global IP rights for its cell therapy.

Summary

• NKGen Biotech has entered into a conditional investment agreement to acquire NKMax Co., Ltd., a company undergoing rehabilitation in South Korea.
• NKGen was selected as the stalking horse bidder in a limited competitive bidding process managed by the Seoul Bankruptcy Court.
• The acquisition involves NKGen subscribing to 46.4 million new shares of NKMax at a price of 500 Korean Won per share, totaling 23.2 billion Korean Won (approximately $18 million).
• NKGen has already deposited 10% of the acquisition price as a security deposit.
• The final terms of the acquisition may be adjusted based on a public competitive bidding process expected to conclude by February 2025.
• If another bidder offers more favorable terms, NKGen has a right of first refusal to match those terms.
• If NKGen is not the final acquirer, they will receive compensation equal to 2% of the original acquisition price.
• NKMax is a clinical-stage biotech company focused on immune cell therapies and holds global IP rights for troculeucel, a therapy being developed by NKGen.
• The acquisition is expected to give NKGen control of the global rights to troculeucel and other proprietary IP.
• NKGen expects to hold a majority of the equity of NKMax at closing.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with the strategic acquisition of NKMax, securing global IP rights and expanding market reach. The risks are acknowledged but presented as manageable, leading to a strong positive sentiment.

Positives

• The acquisition secures global IP rights for troculeucel, a key therapy for NKGen.
• NKGen will gain access to NKMax's GMP-certified manufacturing facility, potentially accelerating production for US trials.
• The acquisition will allow NKGen to commercialize troculeucel in markets where NK cell therapy is already legal, such as Japan and South Korea.
• The close scientific and clinical partnership with the NKMax team will be preserved.
• NKGen believes the NKMax rehabilitation process has not had a material negative impact on its business or prospects.

Negatives

• The acquisition is subject to a public competitive bidding process, which could result in NKGen not being the final acquirer.
• The final terms of the acquisition, including the price, may be adjusted based on the competitive bidding process.
• There is a risk that the rehabilitation plan may be rejected by stakeholders or the court.
• If NKGen terminates the agreement due to NKMax's failure to perform, the deposit will be returned, but if NKMax terminates due to NKGen's failure to perform, the deposit will be forfeited as liquidated damages.

Risks

• The acquisition may not close on the anticipated terms or timing, or at all.
• There is a risk of shareholder litigation in connection with the acquisition.
• The integration of NKMax's business may be more difficult, time-consuming, or costly than expected.
• The successful and timely completion and commercialization of troculeucel is not guaranteed.
• There are risks related to performing clinical studies and potential delays in the commencement, enrollment, and completion of clinical studies.
• NKGen's ability to raise additional funding to complete the development of its product candidates is a risk.

Future Outlook

NKGen expects to hold a majority of the equity of NKMax at closing and to begin commercializing troculeucel in countries where it is already legal. The company also anticipates that the acquisition will strengthen its position and deliver more value for patients and shareholders.

Management Comments

• Paul Y. Song, MD, Chairman and CEO of NKGen Biotech, stated that it was essential to preserve the close scientific and clinical partnership with the NKMax team.
• He also mentioned that the acquisition will allow NKGen to begin commercializing troculeucel in countries where autologous non-genetically modified cell therapy is considered a legal treatment.

Industry Context

This announcement reflects a trend in the biotech industry where companies are consolidating to gain control of key intellectual property and manufacturing capabilities. The acquisition of NKMax by NKGen is a strategic move to secure global rights to troculeucel and expand its market reach.

Comparison to Industry Standards

• Stalking horse bids are a common practice in US bankruptcy proceedings, providing an initial offer that sets a floor for other bids.
• The 2% termination fee is a standard practice to compensate the stalking horse bidder for their time and effort.
• The acquisition of a company undergoing rehabilitation is a complex process, and the outcome is not guaranteed.
• The acquisition of NKMax by NKGen is similar to other biotech acquisitions where companies seek to consolidate intellectual property and manufacturing capabilities.

Legal Proceedings

• NKMax is undergoing rehabilitation proceedings in South Korea, similar to Chapter 11 in the US.

Related Party Transactions

• NKMax is a greater than 10% shareholder of NKGen.

Stakeholder Impact

• Shareholders of NKGen may benefit from the acquisition through increased IP control and market reach.
• Employees of NKMax may have their employment guaranteed for a minimum of 5 years after the rehabilitation termination date.
• Patients may benefit from the commercialization of troculeucel in more markets.
• Creditors of NKMax will be impacted by the rehabilitation plan.

Next Steps

• NKGen will participate in a public competitive bidding process.
• NKGen will decide whether to exercise its right of first refusal if a more favorable bid is received.
• NKGen and NKMax will execute an amended agreement if NKGen exercises its right of first refusal.
• NKGen will deposit the remaining acquisition price balance if selected as the final acquirer.
• The rehabilitation plan will be submitted to the court for approval.
• The acquisition is expected to close in the first quarter of 2025.

Key Dates

Keywords

NKGen Biotech, NKMax, acquisition, stalking horse bid, rehabilitation, troculeucel, cell therapy, intellectual property, biotechnology, M&A